CompletedPhase 1

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

United States, Australia, New Zealand9 participantsStarted 2023-02-18

Plain-language summary

This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Serum creatinine level
✕. Total bilirubin, aspartate aminotransferase or alanine aminotransferase values
✕. Hematological or coagulation values outside the normal reference range

The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).

Timeframe: From Baseline Through Day 180

NCT IDNCT05737485

SponsorReCode Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-07-25